IONS — Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenues: $246 million, an 87% increase year-over-year, driven by strong commercial revenue from Tryngolza and DAWNZERA, along with substantial R&D revenue, including $95 million in milestone payments.
• Commercial Revenue Growth: Increased over 42% year-over-year, with Tryngolza contributing over $27 million and DAWNZERA contributing $16 million (up 125% from the previous quarter).
• Operating Expenses: Increased by 29% year-over-year, primarily due to investments in commercial launches.
• Cash Position: Approximately $1.9 billion, impacted by the repayment of $633 million in convertible notes.
• 2026 Financial Guidance: Total revenue expected to be between $875 million and $900 million, an increase of $75 million from prior guidance. Non-GAAP operating loss projected between $425 million and $475 million, improved by $75 million from previous guidance.

2. Strategic Updates and Business Highlights

• Product Launches:
  • Tryngolza: Strong demand and successful launch in Europe through partner Sobi. Increased peak sales estimate from over $2 billion to over $3 billion due to favorable clinical data and HCP demand.
  • DAWNZERA: Early launch metrics are promising, with significant adoption across patient segments. The product is now approved in Europe.
  • Upcoming Launches: Olezarsen for severe hypertriglyceridemia (SHTG) and Zilganersen for Alexander's disease are on track, with priority reviews from the FDA.
• Pipeline Progress: Continued advancement of partner pipeline, including Bepirovirsen for chronic hepatitis B and ongoing cardiovascular trials.

3. Forward Guidance and Outlook

• Revenue Projections: Expecting Tryngolza sales of $100 million to $110 million and DAWNZERA sales of $110 million to $120 million for 2026.
• Market Positioning: Positioned for cash flow breakeven by 2028, with a diversified revenue model combining commercial and R&D revenues.

4. Bad News, Challenges, or Points of Concern

• Pricing Impact: Anticipated decline in Tryngolza revenue in Q2 due to a price reset, with expectations for a gradual return to growth post-approval for SHTG.
• Market Dynamics: Transitioning patients from existing therapies to new products may take time, particularly in established markets like HAE.
• Regulatory Risks: Dependence on upcoming FDA approvals and the potential for payer delays in coverage decisions.

5. Notable Q&A Insights

• Peak Sales Increase for Tryngolza: Driven by comprehensive HCP and payer research, with a new annual wholesale acquisition cost of $40,000.
• SHTG Launch Expectations: Initial modest growth anticipated, focusing on high-risk patients, with a gradual increase as HCPs gain experience with the product.
• DAWNZERA Competitive Landscape: Strong patient and physician feedback, with a majority of patients expected to start on a 4-week dosing schedule before transitioning to 8-week dosing.
• Zilganersen Market Awareness: Approximately 50% of the estimated 300 patients with Alexander's disease have been identified, with ongoing efforts to increase awareness and treatment access.

Overall, Ionis Pharmaceuticals demonstrated robust growth and strategic momentum in Q1 2026, while navigating challenges associated with pricing and market transitions. The company remains optimistic about its future product launches and pipeline advancements.